Test Price
2,800 AED✅ Home Collection Available
CNOT3 Gene Cardiac Defects Genetic Test in UAE | 2,800 AED | DNA Labs UAE
Executive Summary & Core Metrics
Accuracy Guarantee & Premium Logistics
Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Certified Processing (Cert: INT/EGQ/2509DA/3139).
Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily from 8 AM to 11 PM).
Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation by DHA-licensed physicians.
Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
This CNOT3 NGS test comprehensively evaluates the entire coding region of the CNOT3 gene for pathogenic variants causing congenital heart defects. It is the most advanced next-generation sequencing method available in the UAE, detecting single nucleotide variants, small insertions/deletions, and copy number changes with 99.9% sensitivity. The analysis is performed on the Illumina platform with 100x coverage depth, ensuring high-confidence variant calling for clinical decision-making.
| Feature | Our CNOT3 NGS Test | Conventional Sanger Sequencing |
|---|---|---|
| Precision | 99.9% sensitivity; detects SNVs, indels, CNVs | ~95% for point mutations; misses large rearrangements |
| Methodology | NGS (Illumina platform) with 100x coverage | Bidirectional Sanger of individual exons |
| Turnaround Time | 3–4 Weeks | 4–6 Weeks (for full gene) |
Physician Insight & Safety Protocols
“As a Consultant Medical Genetics specialist, I recognize the profound responsibility that accompanies genetic testing for cardiac conditions. This CNOT3 NGS assay delivers high-resolution molecular data essential for accurate diagnosis of congenital heart defects. However, each result must be interpreted within the full context of the patient's clinical presentation, echocardiographic findings, and three-generation family pedigree. Therapeutic decisions should never be made based solely on genetic data without a comprehensive clinical evaluation.” — Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Advisory – Medication Continuity
Do not discontinue prescribed medication without consulting your doctor. Patients undergoing genetic evaluation for congenital heart defects must maintain all current therapies including antiarrhythmics, anticoagulants, and heart failure medications until explicitly advised otherwise by their cardiologist. Abrupt cessation may lead to hemodynamic instability or thromboembolic events.
Safety Exclusion Criteria & Emergency Red Flags
- Exclusion: Recent blood transfusion (≤ 2 weeks), active systemic infection, bone marrow transplant within 6 months, or current chemotherapy.
- Emergency Red Flags: Seek immediate emergency care if you or your child experiences sudden chest pain, cyanosis (bluish discoloration of skin or lips), severe unexplained shortness of breath, syncope (fainting), or palpitations with dizziness.
Patient FAQ & Clinical Guidance
1. What is the CNOT3 Genetic Test?
CNOT3 next-generation sequencing identifies mutations in the CNOT3 gene causing congenital heart defects with high accuracy.
This test analyses the entire CNOT3 gene using Illumina NGS technology, detecting single nucleotide variants, small insertions/deletions, and copy number changes. It is the definitive molecular tool for diagnosing CNOT3-related cardiac malformations such as atrial septal defects, ventricular septal defects, and tetralogy of Fallot. Results are correlated with clinical and echocardiographic data by our genetics team.
2. Who should consider this test?
Patients with congenital heart defects or a family history of CNOT3-related anomalies should undergo this NGS test.
Ideal candidates include newborns, children, and adults with unexplained congenital heart disease, as well as parents planning future pregnancies after a previous affected child. Pre-test genetic counselling is mandatory to interpret results accurately and to construct a detailed family pedigree. First-degree relatives of a confirmed CNOT3 proband may also benefit from cascade testing.
3. What is the testing process and turnaround time?
Home blood collection is performed by a certified nurse; results take 3–4 weeks using NGS.
A small peripheral blood sample (or one drop on an FTA card) is collected in the comfort of your home under ISO-certified cold-chain protocols. The sample is shipped to our CAP-accredited laboratory for DNA extraction, library preparation, and Illumina NGS sequencing. Bioinformatics analysis and variant interpretation are completed within 21–28 days, followed by a telephonic consultation with a genetics specialist.
4. What does the result report include?
Your report details all detected variants, pathogenicity classifications, and clinical recommendations.
The comprehensive report includes variant coordinates (GRCh38), ACMG/AMP pathogenicity classification, zygosity, population frequency data, in silico prediction scores, and a clinical interpretation section with specific recommendations for cardiac surveillance, surgical planning, and family screening. Reports are reviewed and signed by the Consultant Medical Genetics.
5. Is pre-test genetic counselling required?
Yes, pre-test genetic counselling is mandatory before proceeding with this test.
Our DHA-licensed genetics team provides telephonic or in-person counselling to explain the scope of the test, possible outcomes, implications for family members, and the limitations of variant of uncertain significance (VUS) results. Informed consent is obtained prior to sample collection, in compliance with Federal Decree-Law No. 4 of 2016 on Medical Liability.
UAE Regulatory & Data Privacy Adherence
Personal Data Protection: All genetic data is processed and stored in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Genetic information is encrypted at rest and in transit, accessible only to authorized clinical personnel with explicit patient consent. No data is shared with third parties without prior written authorization. The laboratory operates under DHA Facility License No. 1143 and adheres to the highest standards of confidentiality and data security mandated by UAE law.
Clinical & Logistical Metadata
| Test Name | CNOT3 Gene Cardiac Defects Genetic Test (NGS) |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Peripheral Whole Blood (FTA card also accepted) |
| Methodology Used | Next-Generation Sequencing (NGS) on Illumina Platform, 100x Coverage |
| ICD-10-CM Code | Q24.9, Q21.1, Q21.0 |
| LOINC Code | 81247-9 |
| DHA Facility License & Laboratory Address | DHA Facility License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians